Trastuzumab emtansine and trastuzumab deruxtecan use in three patients with ERBB2-amplified rare tumors
Rare tumors respond to targeted antibody drug treatments
This retrospective case series evaluated three patients with ERBB2-amplified rare tumors, including periampullary, salivary duct, and poorly…
Three patients with rare, aggressive cancers saw significant tumor shrinkage after receiving targeted antibody drug therapies.
QDB method shows higher consistency than IHC for HER2 assessment in invasive breast cancer
New Test Finds Hidden Breast Cancer Targets
This observational cohort study compared a Quantitative Dot Blot (QDB) method to immunohistochemistry (IHC) for HER2 assessment in patients …
Some women told their breast cancer lacks a key target may actually benefit from powerful drugs — a new test can finally tell the difference…
Phase II trial protocol examines HER2-PET imaging to predict trastuzumab deruxtecan response in HER2-low metastatic breast cancer
A Full-Body Scan May Soon Decide Who Benefits From This Breast Cancer Drug
A multicenter, prospective, open-label phase II trial protocol will enroll 70 patients with HER2-low metastatic breast cancer. It will asses…
A whole-body imaging scan may one day replace a single biopsy for matching patients to targeted breast cancer therapy.